Lulizumab pegol
As of the edition of 20 October 2026, Lulizumab pegol is an antibody: stopped in 2022; acts on CD28.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Antibody
- Registered trials
- 5, 3 stopped early
- Disease areas
- Immune system; Bones, joints and muscles; Eye; Mouth and teeth; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Lulizumab pegol.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD28 | T-cell-specific surface glycoprotein CD28 | P10747 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 4 | 2 | 0 | 2 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2014 to now |